The International Committee of Medical Journal Editors (ICMJE) believes there is an ethical obligation to responsibly share data generated by interventional clinical trials because trial participants have put themselves at risk. In January 2016 we published a proposal aimed at helping to create an environment in which the sharing of deidentified individual participant data becomes the norm. In response to our request for feedback we received many comments from individuals and groups.[@R1] Some applauded the proposals while others expressed disappointment they did not more quickly create a commitment to data sharing. Many raised valid concerns regarding the feasibility of the proposed requirements, the necessary resources, the real or perceived risks to trial participants, and the need to protect the interests of patients and researchers.

It is encouraging that data sharing is already occurring in some settings. Over the past year, however, we have learned that the challenges are substantial and the requisite mechanisms are not in place to mandate universal data sharing at this time. Although many issues must be addressed for data sharing to become the norm, we remain committed to this goal.

Therefore, ICMJE will require the following as conditions of consideration for publication of a clinical trial report in our member journals: As of July 1, 2018 manuscripts submitted to ICMJE journals that report the results of clinical trials must contain a data sharing statement as described below.Clinical trials that begin enrolling participants on or after January 1, 2019 must include a data sharing plan in the trial\'s registration. The ICMJE\'s policy regarding trial registration is explained at *[www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html](http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html)*. If the data sharing plan changes after registration this should be reflected in the statement submitted and published with the manuscript, and updated in the registry record.

Data sharing statements must indicate the following: whether individual deidentified participant data (including data dictionaries) will be shared; what data in particular will be shared; whether additional, related documents will be available (e.g., study protocol, statistical analysis plan, etc.); when the data will become available and for how long; by what access criteria data will be shared (including with whom, for what types of analyses and by what mechanism). Illustrative examples of data sharing statements that would meet these requirements are in the [Table](#T1){ref-type="table"}.

###### 

Examples of data sharing statements that fulfill these ICMJE requirements[\*](#TF1){ref-type="table-fn"}.

  --------------------------------------------------------------------------------------------------------------------------
                         Example 1             Example 2                     Example 3                          Example 4
  ---------------------- --------------------- ----------------------------- ---------------------------------- ------------
  Will individual\       Yes                   Yes                           Yes                                No
  participant data\                                                                                             
  be available\                                                                                                 
  (including data\                                                                                              
  dictionaries)?                                                                                                

  What data in\          All of the\           Individual participant\       Individual participant data\       Not\
  particular will be\    individual\           data that underlie the\       that underlie the results\         available
  shared?                participant data\     results reported in this\     reported in this article, after\   
                         collected during\     article, after\               deidentification (text, tables,\   
                         the trial, after\     deidentification (text,\      figures and appendices).           
                         deidentification.     tables, figures, and\                                            
                                               appendices).                                                     

  What other\            Study Protocol,\      Study Protocol,\              Study Protocol                     Not\
  documents will\        Statistical\          Statistical Analysis Plan,\                                      available
  be available?          Analysis Plan,\       Analytic Code                                                    
                         Informed Consent\                                                                      
                         Form, Clinical\                                                                        
                         Study Report,\                                                                         
                         Analytic Code                                                                          

  When will data\        Immediately\          Beginning 3 months and\       Beginning 9 months and\            Not\
  be available (start\   following\            ending 5 years following\     ending 36 months following\        applicable
  and end dates)?        publication. No\      article publication.          article publication.               
                         end date.                                                                              

  With whom?             Anyone who\           Researchers who provide\      Investigators whose proposed\      Not\
                         wishes to access\     a methodologically sound\     use of the data has been\          applicable
                         the data.             proposal.                     approved by an independent\        
                                                                             review committee ("learned\        
                                                                             intermediary") identified for\     
                                                                             this purpose.                      

  For what types of\     Any purpose.          To achieve aims in the\       For individual participant\        Not\
  analyses?                                    approved proposal.            data meta-analysis.                applicable

  By what\               Data are available\   Proposals should be\          Proposals may be submitted\        Not\
  mechanism will\        indefinitely at\      directed to xxx\@yyy. To\     up to 36 months following\         applicable
  data be made\          (*Link to be*\        gain access, data\            article publication. After 36\     
  available?             *included*).          requestors will need to\      months the data will be\           
                                               sign a data access\           available in our University\'s\    
                                               agreement.\                   data warehouse but without\        
                                               Data are available for 5\     investigator support other\        
                                               years at a third party\       than deposited metadata.\          
                                               website. (*Link to be*\       Information regarding\             
                                               *included*)                   submitting proposals and\          
                                                                             accessing data may be found\       
                                                                             at (*Link to be provided*).        
  --------------------------------------------------------------------------------------------------------------------------

These examples are meant to illustrate a range of, but not all, data sharing options.

These initial requirements do not yet mandate data sharing, but investigators should be aware that editors may take into consideration data sharing statements when making editorial decisions. These minimum requirements are intended to move the research enterprise closer to fulfilling our ethical obligation to participants. Some ICMJE member journals already maintain, or may choose to adopt, more stringent requirements for data sharing.

Sharing clinical trial data is one step in the process articulated by the World Health Organization (WHO) and other professional organizations as best practice for clinical trials: universal prospective registration; public disclosure of results from all clinical trials (including through journal publication); and data sharing. Although universal compliance with the requirement to prospectively register clinical trials has not yet been achieved and requires continued emphasis, we must work toward fulfilling the other steps of best practice as well-including data sharing.

As we move forward into this new norm where data are shared, greater understanding and collaboration among funders, ethics committees, journals, trialists, data analysts, participants, and others will be required. We are currently working with members of the research community to facilitate practical solutions to enable data sharing. The United States Office for Human Research Protections has indicated that provided the appropriate conditions are met by those receiving them, the sharing of deidentified individual participant data from clinical trials does not require separate consent from trial participants.2 Specific elements to enable data sharing statements that meet these requirements have been adopted at ClinicalTrials.gov (<https://prsinfo.clinicaltrials.gov/definitions.html#shareData>). The WHO also supports the addition of such elements at the primary registries of the International Clinical Trials Registry Platform. Unresolved issues remain, including appropriate scholarly credit to those who share data, and the resources needed for data access, the transparent processing of data requests, and data archiving. We welcome creative solutions to these problems at [www.icmje.org](http://www.icmje.org).

We envision a global research community in which sharing deidentified data becomes the norm. Working toward this vision will help maximize the knowledge gained from the efforts and sacrifices of clinical trial participants.

Note: This article is being published simultaneously in *Annals of Internal Medicine, BMJ (British Medical Journal), Bulletin of the World Health Organization, Deutsches Ôrzteblatt (German Medical Journal), Ethiopian Journal of Health Sciences, JAMA (Journal of the American Medical Association), Journal of Korean Medical Science, New England Journal of Medicine, New Zealand Medical Journal, PLOS Medicine, The Lancet, Revista Médica de Chile (Medical Journal of Chile)*, and *Ugeskrift for Laeger (Danish Medical Journal)*.
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